Skip to main content
LEQVIO® (inclisiran) injection 284 mg/1.5 mL

LEQVIO® IS A FIRST-IN-CLASS siRNA LIPID-LOWERING THERAPY THAT TARGETS THE LIVER1

LEQVIO prevents formation of PCSK9 protein, allowing more LDL-C receptors to remove circulating LDL-C1

Image of liver

Works selectively in the liver1,2

  • Harnesses the body’s process of RNA interference, which is restricted to the cytoplasm2,3
  • No impact on DNA2,3
LEQVIO the first and only siRNA for LDL-C reduction

Reaches undetectable levels in circulation within 48 hours of administration1

  • Half-life of 9 hours; no accumulation with multiple dosing1

 


 

RNA-induced silencing complex (RISC). Where it loads onto the RNA-induced silencing complex, or RISC.

Prevents the production of PCSK9 protein with an extended duration of 
effect1-3

  • Is slowly released into the cytoplasm and loads onto the RNA-induced silencing complex (RISC)2,3
  • Once loaded, works with RISC to sequentially cleave multiple copies of PCSK9 protein mRNA, which continuously prevents PCSK9 production1,2
  • Less PCSK9 allows for increased LDL-C receptors to bind to and decrease circulating LDL-C1

 


 

Explore the MOA

Explore the MOA

Discover more about how LEQVIO works differently than other LDL-C–lowering treatments as a complement to statins.

Dive into siRNA technology

Dive into siRNA technology

Read the infographic to learn more about LEQVIO—a small interfering RNA therapy that selectively targets the liver to regulate LDL-C levels.

There's more to know about LEQVIO

See essential dosing and administration information for LEQVIO

DNA, deoxyribonucleic acid; LDL-C, low-density lipoprotein cholesterol; MOA, mechanism of action; mRNA, messenger ribonucleic acid; PCSK9, proprotein convertase subtilisin/kexin type 9; RNA, ribonucleic acid; siRNA, small interfering ribonucleic acid.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 3. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;3761(1):41-51. doi:10.1056/NEJMoa1609243